NTBLQ (Notable Labs) Notes Receivable: $0.00 Mil (As of Jun. 2024)


What is Notable Labs Notes Receivable?

Notable Labs NTBLQ -90.00% Notes Receivable is $0.00 Mil as of Jun. 2024.

Notable Labs's Notes Receivable for the quarter that ended in Jun. 2024 was $0.00 Mil.

Notable Labs Notes Receivable Historical Data

* Premium members only.

The historical data trend for Notable Labs's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Notable Labs Notes Receivable Chart

Notable Labs Annual Data
Trend Dec21 Dec22 Dec23
Notes Receivable
0.00 0.00 0.00

Notable Labs Quarterly Data
Dec21 Dec22 Mar23 Jun23 Dec23 Mar24 Jun24
Notes Receivable Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Notable Labs Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
Notable Labs (NTBLQ) has a Notes Receivable of $0.00 Mil as of Jun. 2024. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Notable Labs and its competitors.
Is Notable Labs' Notes Receivable too high?
Notable Labs' current Notes Receivable is $0.00 Mil.
How does Notable Labs' Notes Receivable compare to VRTX and REGN?
Notable Labs' Notes Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Notable Labs and its competitors. Notable Labs's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Notable Labs stock overvalued right now?
Notable Labs (NTBLQ) has a current Notes Receivable of $0.00 Mil. The current Notes Receivable is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Notable Labs (NTBLQ), the current Notes Receivable is $0.00 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Notable Labs Business Description

Address 320 Hatch Drive, Foster City, CA, USA, 94404
Notable Labs Ltd is a clinical-stage platform therapeutics company developing predictive precision medicines for patients with cancer. Through its proprietary Predictive Precision Medicines Platform (PPMP), Notable bio-simulates a cancer treatment to predict whether or not a patient is likely to respond to that specific therapeutic. PPMP is designed to enable Notable to identify and select patients expected to be clinically responsive before the initiation of their treatment and potentially enable fast-track therapeutic development in this patient population.